Art

J-GLOBAL ID：201502217030861999   Reference number：15A0942683

Functional Mechanism(s) of the Inhibition of Disease Progression by Combination Treatment with Fingolimod Plus Pathogenic Antigen in a Glucose-6-phosphate Isomerase Peptide-Induced Arthritis Mouse Model

グルコース-6-リン酸イソメラーゼペプチド誘発性関節炎マウスモデルにおけるフィンゴリモド+病原抗原の併用処理による疾患進行阻害の機能的機序

Author (12)： YOSHIDA Yuya (Dep. of Pathological Biochemistry, Fac. of Pharmaceutical Sciences, Setsunan Univ.) ,  MIKAMI Norihisa (Lab. of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka Univ.) ,  MATSUSHIMA Yuki (Dep. of Pathological Biochemistry, Fac. of Pharmaceutical Sciences, Setsunan Univ.) ,  OTANI Fumiya (Dep. of Pathological Biochemistry, Fac. of Pharmaceutical Sciences, Setsunan Univ.) ,  MIYAWAKI Mai (Dep. of Pathological Biochemistry, Fac. of Pharmaceutical Sciences, Setsunan Univ.) ,  TAKATSUJI Miku (Lab. of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka Univ.) ,  BANNO Rie (Dep. of Pathological Biochemistry, Fac. of Pharmaceutical Sciences, Setsunan Univ.) ,  TSUJI Takumi (Dep. of Pathological Biochemistry, Fac. of Pharmaceutical Sciences, Setsunan Univ.) ,  FUJITA Tetsuro (Res. Inst. for Production and Dev.) ,  TSUJIKAWA Kazutake (Lab. of Molecular and Cellular Physiology, Graduate School of Pharmaceutical Sciences, Osaka Univ.) ,  KOHNO Takeyuki (Dep. of Pathological Biochemistry, Fac. of Pharmaceutical Sciences, Setsunan Univ.) ,  KOHNO Takeyuki (Res. Inst. for Production and Dev.)
Material： Biological and Pharmaceutical Bulletin  (Biological & Pharmaceutical Bulletin)
Volume： 38  Issue： 8  Page： 1120-1125 (J-STAGE)  Publication year： 2015 
JST Material Number： S0989A  ISSN： 0918-6158  CODEN： BPBLEO  Document type： Article
Article type： 原著論文  Country of issue： Japan (JPN)  Language： ENGLISH (EN)

Thesaurus term： Mus musculus ,...
Semi thesaurus term： PD-1 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=15A0942683&from=J-GLOBAL&jstjournalNo=S0989A") }}

JST classification (1)： Basic medicine on musculoskeletal system  (GG01020B)

Substance index (1)： Fingolimod

Reference (34)：

• 1) Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. Lancet, 376, 1094-1108 (2010).
• 2) Gumanovskaya ML, Myers LK, Rosloniec EF, Stuart JM, Kang AH. Intravenous tolerization with type II collagen induces interleukin-4- and interleukin-10-producing CD4⁺ T cells. Immunology, 97, 466-473 (1999).
• 3) Li H, Ciric B, Yang J, Xu H, Fitzgerald DC, Elbehi M, Fonseca-Kelly Z, Yu S, Zhang GX, Rostami A. Intravenous tolerance modulates macrophage classical activation and antigen presentation in experimental autoimmune encephalomyelitis. J. Neuroimmunol., 208, 54-60 (2009).
• 4) Jiang Z, Li H, Fitzgerald DC, Zhang GX, Rostami A. MOG_35-55 i.v. suppresses experimental autoimmune encephalomyelitis partially through modulation of Th17 and JAK/STAT pathways. Eur. J. Immunol., 39, 789-799 (2009).
• 5) Yoshida Y, Tsuji T, Watanabe S, Matsushima A, Matsushima Y, Banno R, Fujita T, Kohno T. Efficacy of combination treatment with fingolimod (FTY720) plus pathogenic autoantigen in a glucose-6-phosphate isomerase peptide (GPI_325-339)-induced arthritis mouse model. Biol. Pharm. Bull., 36, 1739-1746 (2013).

Terms in the title (9)： グルコース ,  リン酸 ,  関節 ,  マウスモデル ,  フィンゴリモド ,  抗原 ,  併用 ,  疾患進行 ,  阻害